updated phase i results from sgnbcma-001 study of sea-bcma in patients with r/r multiple myeloma
Published 1 year ago • 65 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
3:45
update on phase i trial of teclistamab in r/r myeloma
-
12:17
updated iv and sc results from a phase i dose escalation study of forimtamig with rrmm patients
-
2:43
updated results from majestec-1
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
5:22
magrolimab azacitidine in mds and aml
-
8:18
car-t therapy in acute and chronic leukemias: where are we now and where are we heading?
-
1:59
the growing importance of celmods in the treatment of r/r multiple myeloma
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
3:23
updated safety and efficacy results of abbv-383, a novel bsab, in patients with r/r multiple myeloma
-
2:01
real-world results of an in-class transition from vrd to ird in myeloma
-
1:39
phase i/ii trial of adct-602 in b-all
-
1:07
final results of a phase ii study of add-on parsaclisib for pts with mf and suboptimal rux response
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
1:14
the potential of celmods for the treatment of r/r multiple myeloma
-
2:00
an update on the genomic landscape of mm
-
6:00
covid-19 and mpn updates
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma